Iclusig (ponatinib) VERSUS Gleevec (imatinib)

Share:

3 Innovative Biotech Companies With Promising Cancer Therapies
Seeking Alpha
The global, Phase III EPIC trial which compares Iclusig to Novartis’ blockbuster drug Gleevec (imatinib) in patients with newly diagnosed CML, is advancing. The company expects to reach full patient enrollment in the fourth quarter of 2013 …

http://seekingalpha.com/article/1467241-3-innovative-biotech-companies-with-promising-cancer-therapies?source=google_news

Tweet